Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Cacaito who wrote (1224)	9/10/1998 6:29:00 PM
From: yosi s	Read Replies (1) \| Respond to of 1491

Well I know little about Zeneca . But Tamoxiphen is available in generic in Europe. As to PARS product they have animal study only. what they noted was that Their analogue was able to decrease tumor size and is acting like antiangiogenesis product. That is the excitement. It may be more effective as antineoplastic not only as adjuvent or prevention only. That is why clinical work as to be done. And lots of basic research that is why PARS wants a partner early on but as a product it is 2-3 yrs behind HU211. This is important to show very promising pipeline. It will give credit to pars only when they get partner and go into phase 1 etc. As to HU211 we can gather that it is safe. No safety issue were noted. As they have independent safety committee and where allowed to increase size of study. As to efficacy we know that there are only 8 death in the study 67 patients , expect 7-1 or 6-2 ad then the placebo group is well on the low side of similar groups, even with 8 -0 placebo is still well within range. But we need to wait until October. as death rate with 8 people can still be all over the place. But if deeath rate is 6-2 or 7-1 and those that survive shows similar rate of improvement than we can safly project that the phase 3 study will prove HU211 efficacy. As to market size. There are 500000 severe headtrauma patients and 2 million that are admited to ER with some head trauma. so the market size is minimum 1/2 million, and up to 2 million probably 1 million may get some treatment in ER if it is proven safe and effective. that is only Traumatic Brain Injury. Add stroke. Cardiac arrest where there is potential for brain injury and the market size increases etc etc. Treatment cost per patient are projected to be 1000 minimum to 1800 . and with no current therapy market pnetration will be swift. Especially if PARS is able to set up their study centers at major institutions, So the investigators will be HU211 biggest advocates. Marketing will be build in into the study......